Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.30%
#2 Victoria VR Victoria VR +9.12%
#3 Movement Movement +8.40%
#4 COTI COTI +7.33%
#5 DMT-NAT DMT-NAT +6.93%
#6 Palladium Network Palladium Network +4.63%
#7 Prom Prom +4.55%
#8 Test Test +4.07%
#9 GRVT Token GRVT Token +3.80%
#10 Cryptopia Cryptopia +3.74%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
Kedudukan dalam Saham #1377
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Harga Saham
$49.68
Disegerakkan terakhir: 2026-08-12
Modal Pasaran
$17.25B
Perubahan (1 hari)
0.77%
Perubahan (1 tahun)
72.21%
Negara
SE
Perdagangan Swedish Orphan Biovitrum AB (SOBI)

Kategori

Healthcare
Hasil untuk Swedish Orphan Biovitrum AB (SOBI)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Swedish Orphan Biovitrum AB, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Swedish Orphan Biovitrum AB dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 $4.55B -
HK